Täiskasvanute Kõrgvererõhktõve Käsitlus Esmatasandil

Objectives

The 2019 Estonian primary-care guideline aims to improve the diagnosis, treatment and monitoring of essential hypertension in adults, reducing cardiovascular complications, premature mortality, organ damage and loss of work capacity while preserving quality of life.[1][2]It treats raised blood pressure as a major modifiable cardiovascular risk factor associated with stroke, myocardial infarction, heart failure, kidney damage and cognitive impairment.[3]The guideline updates the 2012 adult-hypertension guideline, retaining recommendations where new evidence did not justify change and identifying amended or new recommendations.[1][2]

• Strengthen early and accurate diagnosis through standardised clinic measurement, home blood-pressure monitoring and, where possible, 24-hour automated ambulatory blood-pressure monitoring.[4][5][6]
• Assess overall cardiovascular risk, organ damage, comorbidities and possible secondary hypertension alongside blood-pressure classification.[5][7][8]
• Reduce cardiovascular risk through patient education, lifestyle change, non-pharmacological care and appropriately selected antihypertensive medicines.[9][10][11]
• Achieve individualised blood-pressure targets, generally 120–130/80 mmHg for people under 65 years and 130–140/80 mmHg for those over 65 years, while accounting for treatment tolerance, diabetes and organ damage.[12][13]
• Improve treatment adherence through affordable clinically appropriate prescribing, shared treatment planning, home monitoring, reminders, family support and combination preparations where suitable.[14][15][16]
• Prevent complications through stepwise treatment escalation, specialist referral for resistant or suspected secondary hypertension, and regular review of clinical response.[17][14][18]

Implementation

Delivery is centred on Estonian primary care, where family doctors and other primary-care professionals diagnose hypertension, prescribe treatment and monitor patients.[1][2]The guideline was developed through a multidisciplinary process involving family medicine, cardiology, nephrology, nursing, academia, professional organisations and the Estonian Health Insurance Fund.[19][20]Recommendations were developed under the Estonian guideline-development handbook using evidence appraisal, consensus decisions and consideration of benefits, harms, patient preferences, feasibility, resource use and economic justification.[21][22][23][24]

• Use validated, calibrated blood-pressure devices with appropriately sized cuffs and standardised measurement conditions; device administrators are responsible for mandatory metrological control and the two-year verification period for devices used in healthcare.[25][26][27]
• Repeat clinic readings of at least 140/90 mmHg during the same visit and confirm suspected hypertension through 24-hour ambulatory monitoring where feasible, using home monitoring when ambulatory monitoring is unavailable or not tolerated.[5][28][6]
• Conduct initial assessment through history-taking, physical examination, cardiovascular-risk assessment, laboratory testing, urine testing, electrocardiography and fundoscopy for grade 3 hypertension or diabetes.[29][7]
• Provide lifestyle counselling on salt reduction, physical activity, alcohol, smoking and healthy weight, including a salt intake below 5 grams daily and moderate-intensity aerobic exercise for 30–60 minutes on five to seven days each week.[10][30][31]
• Initiate pharmacotherapy immediately alongside non-pharmacological care for high-risk grade 1 hypertension in people under 80 years and for grade 2 hypertension regardless of age; use treatment choices that reflect comorbidities, contraindications, benefit, harm and affordability.[9][13][32]
• Start with an angiotensin-converting enzyme inhibitor or calcium-channel blocker where no comorbidity dictates another class, consider two-drug therapy when blood pressure is at least 20/10 mmHg above target or cardiovascular risk is very high, and tailor medicines for diabetes, chronic kidney disease, heart failure, coronary disease and pregnancy-related contraindications.[13][33][34]
• Intensify or adjust therapy every four weeks, usually reaching target values within two to three months; after inadequate response, combine recommended medicine classes, add low-dose spironolactone as fourth-line treatment where renal function and potassium permit, and refer to a specialist only after confirmed adherence and unsuccessful maximally tolerated four-drug therapy.[13][18][35]
• Support adherence through explanation of treatment needs and adverse effects, agreed care plans, family-nurse telephone counselling, pill boxes or other reminders, family involvement and fixed-dose combinations where medically appropriate.[14][15][36]
• Monitor clinical care through blood-pressure measurements, treatment-response assessment, adherence checks, annual treatment review and renal-function and electrolyte monitoring after spironolactone initiation.[12][14][35]
• Implement and evaluate activities through a published implementation plan on ravijuhend.ee; supporting materials include evidence summaries, meeting minutes, declarations of interests and the full guideline.[20][23]The guideline is scheduled for review after five years or earlier if relevant new evidence emerges.[23][37]

Monitoring & Evaluation

The guideline combines clinical monitoring of diagnosis, cardiovascular risk, treatment response and adherence with implementation-plan evaluation and periodic evidence review. It does not specify a national surveillance system, routine reporting timetable or comprehensive accountability framework.[38][20][23]

• Use validated, calibrated blood-pressure devices and ensure mandatory metrological control, for which the device administrator is responsible; verification remains valid for two years.[25][26][39]
• Diagnose and monitor hypertension through clinic, home and ambulatory blood-pressure measurement, repeating ambulatory monitoring if fewer than 14 waking-period readings are available.[40][39]
• Apply 24-hour ambulatory monitoring as the standard diagnostic method where tolerated, including night-time readings, while allowing shorter monitoring periods at clinical discretion where 24-hour monitoring is impractical or disrupts sleep.[6]
• Assess overall cardiovascular risk whenever hypertension is suspected, including organ damage, diabetes, chronic kidney disease, established cardiovascular or renal disease and other risk factors.[5][7][8]
• Undertake diagnostic assessment using history, examination, laboratory tests, urine testing, electrocardiography and, for grade 3 hypertension or diabetes, fundoscopy.[29][7]
• Measure treatment effectiveness principally through blood pressure at clinical visits, supplementing this with home measurement where white-coat hypertension is suspected.[9][41]
• Review or intensify treatment every four weeks until target blood pressure is achieved, normally within two to three months according to treatment tolerance.[13][42]
• Assess response after eight weeks following treatment initiation or intensification; before specialist referral, confirm correct medicine use and allow two to three months for optimised treatment.[17][14][18]
• Monitor estimated glomerular filtration rate and electrolytes after initiating spironolactone, and review treatment and adherence at least annually.[35][15]
• Assess adherence through patient discussion and, where appropriate, electronic monitoring, tablet counts, prescription collection records or patient-reported information.[14][43]
• Document physical activity and review salt-reduction progress at every clinical visit as part of lifestyle follow-up.[44]
• Use prioritised outcome indicators covering acute myocardial infarction, stroke, cardiovascular mortality, end-stage renal disease, heart failure, achievement of blood-pressure targets, adverse-effect-related discontinuation, quality of life, adherence, hospitalisation, patient satisfaction, renal function, work-disability days and treatment cost.[45]
• Evaluate implementation through a published implementation plan and make supporting materials, including evidence summaries, meeting minutes and declarations of interests, publicly available.[20][23]
• Review and update the guideline five years after approval, or earlier if relevant new evidence emerges.[23][37]

Costing & Financing

No implementation budget, funding allocation, financing mechanism, resource-mobilisation plan, quantified funding gap or programme-level economic assumption is specified. Resource use, affordability and economic justification are nevertheless considered when recommendations are developed.[22][24]

• Consider the most affordable recommended starting dose of an angiotensin-converting enzyme inhibitor or calcium-channel blocker where comorbidity does not require a particular medicine group.[13][32]
• Use the cheapest suitable angiotensin receptor blocker when replacing an effective angiotensin-converting enzyme inhibitor that causes troublesome cough.[17][18]
• Recognise that lower unavoidable patient co-payment is associated with better medicine adherence, although the evidence is of low certainty and no monetary financing recommendation is provided.[43][20]
• Consider combination preparations rather than separate tablets where medically appropriate, including affordability among the factors considered.[15]
• Use existing ambulatory blood-pressure monitoring equipment without additional cost where the clinician already has a device.[6]
• Note that a United Kingdom model found automated ambulatory monitoring to be the most cost-effective diagnostic method, principally by avoiding unnecessary treatment, while an Estonian Health Insurance Fund analysis found monitoring all patients was probably less costly than avoidable pharmacotherapy.[46][47]
• Recognise that a Belgian analysis found home-measurement-guided treatment saved costs but achieved poorer blood-pressure control, and that no economic analysis applicable to Estonian conditions was identified for this comparison.[48]
• Recognise that lower blood-pressure targets were associated with higher costs without a difference in hypertension-complication frequency in one analysis using Swedish cost data.[49]
• Recognise that angiotensin-converting enzyme inhibitors or angiotensin receptor blockers were reported to be clinically more beneficial and less costly than other medicine groups for patients with kidney damage.[50]
• Recognise that a low-quality Swiss model judged antihypertensive treatment for people aged 80 years and over to be cost-effective, without specifying a programme financing arrangement.[51]